These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25574617)

  • 41. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy.
    Hayes D; Long FR; McCoy KS; Sheikh SI
    Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273
    [No Abstract]   [Full Text] [Related]  

  • 42. Sweat chloride is not a useful marker of clinical response to Ivacaftor.
    Barry PJ; Jones AM; Webb AK; Horsley AR
    Thorax; 2014 Jun; 69(6):586-7. PubMed ID: 24258833
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Update in cystic fibrosis 2013.
    Jain M; Goss CH
    Am J Respir Crit Care Med; 2014 May; 189(10):1181-6. PubMed ID: 24832742
    [No Abstract]   [Full Text] [Related]  

  • 44. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CFTR potentiators: not an open and shut case.
    Clancy JP
    Sci Transl Med; 2014 Jul; 6(246):246fs27. PubMed ID: 25101884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Breathing easier with combinations.
    Azvolinsky A
    Nat Biotechnol; 2015 Nov; 33(11):1128-30. PubMed ID: 26544137
    [No Abstract]   [Full Text] [Related]  

  • 48. [Cystic Fibrosis: toward a genetic treatment; Clostridium difficile versus Clostridium difficile].
    Nau JY
    Rev Med Suisse; 2015 May; 11(476):1210-1. PubMed ID: 26182641
    [No Abstract]   [Full Text] [Related]  

  • 49. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
    Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
    J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cystic fibrosis--what are the prospects for a cure?
    Kumar S; Tana A; Shankar A
    Eur J Intern Med; 2014 Nov; 25(9):803-7. PubMed ID: 25447947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modifying disease in cystic fibrosis: current and future therapies on the horizon.
    Ong T; Ramsey BW
    Curr Opin Pulm Med; 2013 Nov; 19(6):645-51. PubMed ID: 24048086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation.
    Ronan NJ; Fleming C; O'Callaghan G; Maher MM; Murphy DM; Plant BJ
    Chest; 2015 Sep; 148(3):e72-e75. PubMed ID: 26324139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [FUTURE THERAPIES FOR CYSTIC FIBROSIS].
    Fajac I
    Rev Prat; 2015 Oct; 65(8):1106-8. PubMed ID: 26749719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cystic fibrosis: bridging the treatment gap in early childhood.
    Davies JC
    Lancet Respir Med; 2013 Aug; 1(6):433-4. PubMed ID: 24429232
    [No Abstract]   [Full Text] [Related]  

  • 55. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Orkambi's Slick Unveiling Puts Insurers in a Bind.
    Silverman E
    Manag Care; 2015 Aug; 24(8):16-7. PubMed ID: 26399136
    [No Abstract]   [Full Text] [Related]  

  • 57. Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi.
    Hollis A
    Healthc Policy; 2019 Aug; 15(1):70-80. PubMed ID: 31629457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Therapeutic update in cystic fibrosis].
    Durupt S; Nove Josserand R; Durieu I
    Rev Med Interne; 2014 Jun; 35(6):388-92. PubMed ID: 24309546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy.
    Hayes D; Warren PS; McCoy KS; Sheikh SI
    J Pediatr Gastroenterol Nutr; 2015 May; 60(5):578-9. PubMed ID: 25688481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.